Figure/Table Caption List
Figure 1A.
Clinical courses of 19 cases with placental removal within 24 hours after delivery
The numbers in “Size and blood flow of RPOC” indicate the size of RPOC (mm).
The numbers in “After” and “Disappearance of RPOC” indicate the duration from delivery to the onset of the events (days).
RPOC, retained products of conception
Figure 1B.
Clinical courses of 22 cases with conservative management.
The number in “Size and blood flow of RPOC” indicate the RPOC size (mm).
The number in “Events” and “Disappearance of RPOC” indicate the duration from delivery to the onset of event (days).
RPOC, retained products of conception
Figure 2.
The cumulative incidence rate of events in RPOC cases with conservative management
The horizontal and vertical axes represent the duration from delivery to the onset of the events (days) and the incidence rate (%), respectively.
Cumulative incidence rates of heavy bleeding (A), blood transfusion (B), UAE (C), and infection (D) in 22 cases with conservative management of RPOC.
Cumulative incidence rates of heavy bleeding (E), blood transfusion (F), UAE (G), and infection (H) in 16 cases without placental extraction trial during conservative management, excluding five cases with placental traction and one with D&C
RPOC, retained products of conception; UAE, uterine artery embolization; D&C, dilatation and curettage
Figure 3.
The cumulative rate of placental resolution in RPOC cases with conservative management
The horizontal and vertical axes indicate the duration from delivery to resolution (days) and the cumulative incidence rate (%), respectively. Arrows and arrow head indicate the timing of MROP and TCR, respectively.
RPOC, retained products of conception; MROP, manual removal of the placenta; TCR, transcervical resection
Figure 4.
Serial changes in serum hCG
The horizontal and vertical axes indicate the duration from delivery to the measurement date (days) and the serum hCG level (IU/L), respectively.
(A)(B) RPOC cases delivered after 34 weeks of gestation
(A) Cases without UAE.
(B) Cases with UAE. Arrows show the date on which UAE was performed.
(C)(D) RPOC cases delivered at less than 20 weeks of gestation and did not undergo UAE
(C) Cases with serum hCG half-life of less than 10 days
(D) Cases with serum hCG half-life of more than10 days
RPOC, retained products of conception; UAE, uterine artery embolization; hCG, human chorionic gonadotropin
Figure S1.
Representative images of RPOC cases with conservative management
(A) Case 23: Contrast-enhanced CT with heavy bleeding showed strongly contrast-enhanced RPOC in the arterial phase (postpartum day10). Arrows show RPOC.
(B)-(F) case 37: Serial changes in contrast-enhanced MRI during conservative management
(B) Sagittal T2WI showed an RPOC in the uterus. The RPOC size was 72 x 42 x 49 mm (postpartum day 3).
(C) Sagittal contrast T1WI demonstrated strongly contrasted RPOC (postpartum day 3).
(D) Sagittal T2WI showed RPOC in the uterus, whose size became smaller. The RPOC size was 22 x 17 x 15 mm (postpartum day 22).
(E) Sagittal contrast T1WI still demonstrated strongly contrasted RPOC (postpartum day 22).
(F) MRI did not detect RPOC (postpartum day 64). Ultrasound showed RPOC of 8 mm on postpartum day 87. On postpartum day 102, hysteroscopy showed that the RPOC was 10 mm, and on postpartum day 201, it was finally confirmed that the RPOC had disappeared.
CT, computed tomography; RPOC, retained products of conception; MRI, magnetic resonance imaging; T2WI, T2-weighted imaging
Table S1.
Univariate analysis between RPOC with heavy bleeding and light bleeding during conservative management
RPOC, retained products of conception
References
1. Tunçalp O, Souza JP, Gülmezoglu M: New WHO recommendations on prevention and
treatment of postpartum hemorrhage. Int J Gynaecol Obstet 2013, 123:254-256.
2. Weissbach T, Haikin-Herzberger E, Bacci-Hugger K, Shechter-Maor G, Fejgin M,
Biron-Shental T: Immediate postpartum ultrasound evaluation for suspected retained placental tissue in patients undergoing manual removal of placenta. Eur J Obstet Gynecol Reprod Biol 2015, 192:37-40.
3. Hoveyda F, MacKenzie IZ: Secondary postpartum haemorrhage: incidence, morbidity
and current management. Bjog 2001, 108:927-930.
4. Urner F, Zimmermann R, Krafft A: Manual removal of the placenta after vaginal
delivery: an unsolved problem in obstetrics. J Pregnancy 2014, 2014:274651.
5. Anteby M, Many A, Ashwal E, Yogev Y, Shinar S. Risk factors and complications of
manual placental removal after vaginal delivery - how common are additional invasive procedures? J Matern Fetal Neonatal Med. 2019, 32:384-388.
6. Takahashi H, Ohhashi M, Baba Y, Nagayama S, Ogoyama M, Horie K, et al.:
Conservative management of retained products of conception in the normal placental position: A retrospective observational study. Eur J Obstet Gynecol Reprod Biol 2019, 240:87-92.
7. Wada Y, Takahashi H, Suzuki H, Ohashi M, Ogoyama M, Nagayama S, et al.:
Expectant management of retained products of conception following abortion: A retrospective cohort study. Eur J Obstet Gynecol Reprod Biol 2021, 260:1-5.
8. Kobayashi M, Nakagawa S, Kawanishi Y, Masuda T, Maenaka T, Toda A, et al.: The
RPOC long axis is a simple indicator for predicting the need of invasive strategies for secondary postpartum hemorrhage in either post-abortion or post-partum women: a retrospective case control study. BMC Pregnancy Childbirth 2021, 21:653.
9. Sentilhes L, Ambroselli C, Kayem G, Provansal M, Fernandez H, Perrotin F et al:
Maternal outcome after conservative treatment of placenta accreta. Obstet Gynecol 2010, 115:526-534.
10. Foreste V, Gallo A, Manzi A, Riccardi C, Carugno J, Sardo ADS. Hysteroscopy and Retained Products of Conception: An Update. Gynecol Minim Invasive Ther. 2021, :203-209.
11. Vitale SG, Parry JP, Carugno J, Cholkeri-Singh A, Della Corte L, Cianci S et al. Surgical and Reproductive Outcomes after Hysteroscopic Removal of Retained Products of Conception: A Systematic Review and Meta-analysis. J Minim Invasive Gynecol. 2021, 28:204-217.
12. Pather S, Ford M, Reid R, Sykes P. Postpartum curettage: an audit of 200 cases. Aust N Z J Obstet Gynaecol. 2005, 45:368-71.
13. Imai S, Kondoh E, Kawasaki K, Mogami H, Ueda A, Umeoka S et al. : Placental blood flow disappears coincident with a fall in human chorionic gonadotropin to undetectable levels in conservative management of placenta accreta. Eur J Obstet Gynecol Reprod Biol 2014, 180:199-201.
14. Miyakoshi K, Otani T, Kondoh E, Makino S, Tanaka M, Takeda S: Retrospective
multicenter study of leaving the placenta in situ for patients with placenta previa on a cesarean scar. Int J Gynaecol Obstet 2018, 140:345-351.
15. Kamaya A, Krishnarao PM, Nayak N, Jeffrey RB, Maturen KE: Clinical and imaging
predictors of management in retained products of conception. Abdom Radiol (NY) 2016, 41:2429-2434.
16. Hooker AB, Aydin H, Brölmann HA, Huirne JA: Long-term complications and reproductive outcome after the management of retained products of conception: a systematic review. Fertil Steril 2016, 105:156-164.e151-152.
17. Fujita K, Ushida T, Imai K, Nakano-Kobayashi T, Iitani Y, Matsuo S, et al.
: Manual removal of the placenta and postpartum hemorrhage: A multicenter retrospective study. J Obstet Gynaecol Res 2021, 47:3867-3874.
18. Ikeda A, Kondoh E, Chigusa Y, Mogami H, Kameyama Nakao K, et al. Novel subtype of atonic postpartum hemorrhage: dynamic computed tomography evaluation of bleeding characteristics and the uterine cavity. J Matern Fetal Neonatal Med. 2020, 33:3286-3292.
19. Furukawa S, Fujisaki M, Maki Y, Oohashi M, Doi K, Sameshima H. Manual removal of placenta in women having unpredictable adherent placenta. J Obstet Gynaecol Res. 2019, 45:141-147.
20. Creasy & Resnik’s Maternal-FETAL MEDICINE Principles and Practice 8th EDITION
21. Akiba N, Iriyama T, Nakayama T, Seyama T, Sayama S, Kumasawa K, et al.
: Ultrasonographic vascularity assessment for predicting future severe hemorrhage in retained products of conception after second-trimester abortion. J Matern Fetal Neonatal Med 2021, 34:562-568.
22. Shitanaka S, Chigusa Y, Kawahara S, Kawasaki K, Mogami H, Mandai M, et al.:
Conservative management for retained products of conception after less than 22 weeks of gestation. J Obstet Gynaecol Res 2020, 46:1982-1987.
23. Grewal K, Al-Memar M, Fourie H, Stalder C, Timmerman D, Bourne T: Natural
history of pregnancy-related enhanced myometrial vascularity following miscarriage. Ultrasound Obstet Gynecol 2020, 55:676-682.
24. Midgley AR Jr, Jaffe RB. Regulation of human gonadotropins. II. Disappearance of human chorionic gonadotropin following delivery. J Clin Endocrinol Metab. 1968, 28:1712-8.
25. Matsumura N, Inoue T, Fukuoka M, Sagawa N, Fujii S. Changes in the serum levels of human chorionic gonadotropin and the pulsatility index of uterine arteries during conservative management of retained adherent placenta. J Obstet Gynaecol Res. 2000, 26:81-7.
26. Fernandez H, Bourget P, Ville Y, Lelaidier C, Frydman R. Treatment of unruptured tubal pregnancy with methotrexate: pharmacokinetic analysis of local versus intramuscular administration. Fertil Steril. 1994, 62:943-7.
27. Ozeren M, Bilekli C, Aydemir V, Bozkaya H. Methotrexate and misoprostol used alone or in combination for early abortion. Contraception. 1999, 59:389-94.